SCHEMBL3159588

SCHEMBL3159588

On1c(-c2ccccc2)c[nH]c1=S

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.59
HPGD P15428 6/20 0.59
GAA P10253 4/20 0.59
KMT2A Q03164 3/20 0.59
MEN1 O00255 1/20 0.59
NPC1 O15118 1/20 0.58
ALOX12 P18054 1/20 0.58
RAB9A P51151 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
KDM4E B2RXH2 5/20 0.56
MAPT P10636 3/20 0.53
HTT P42858 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MAPK1 P28482 1/20 0.51
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
RXFP1 Q9HBX9 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
GLO1 Q04760 1/20 0.39
GFER P55789 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5312485 0.81 ALDH1A1 (0.53) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL3173737 0.77 ALOX12 (0.42) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL2821098 0.76 NPC1 (0.93) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL17446071 0.74 ALDH1A1 (1.00) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL3180401 0.74 MAPT (0.49) ALDH1A1GAAKMT2AMEN1NPC1
SCHEMBL3174401 0.73 ALDH1A1 (0.46) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL17446077 0.73 NPC1 (0.59) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL17446083 0.73 NPC1 (1.00) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL19130180 0.72 ALDH1A1 (1.00) ALDH1A1HPGDGAAKMT2AMEN1
SCHEMBL3174701 0.72 NPC1 (0.57) ALDH1A1HPGDGAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100010049-A1 Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-01-14 US disclosed
US-20100010049-A1 Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-01-14 US disclosed
US-20100010049-A1 Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-01-14 US disclosed
EP-2041095-A1 NOVEL TYROSINASE INHIBITORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2009-04-01 EP disclosed
WO-2008006824-A1 NOVEL TYROSINASE INHIBITORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-01-17 WO disclosed
WO-2007039821-A2 NOVEL INHIBITORS OF TYROSINASE, THEIR METHOD OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010049-A1 Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof TYR, MITF, MAOA ALDH1A1 69/4885HPGD 373/4885GAA 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.